

**Errata to the Briefing Document  
Oncologic Drugs Advisory Committee Meeting (ODAC)  
July 13, 2017**

**BLA 761028, ABP215 (bevacizumab Biosimilar Candidate)**

**Applicant: Amgen Inc.**

The erroneous text is found in Section 1 of the Executive Summary in the briefing book and is identified by a strikethrough with corrections identified in bold below.

The missing value is displayed in Figure 5 on the next page (p. 14). Additionally, fully detailed, correct information regarding clinical efficacy similarity study results is provided in Section 5.2 Clinical Efficacy.

**1. Page 13,**

~~uct is licensed that w~~**The ORR was 39.0% for ABP 215 and 41.7% for bevacizumab in the intent-to-treat population.**